08 Aug 2019
Posted in Pharma
Diagnosed ovarian cancer cases set to reach 66,000 across seven major markets in 2028
The diagnosed incident cases of ovarian cancer in the seven major markets (7MM*) will increase at an annual growth rate (AGR) of 0.42% from over 63,000 cases in 2018 to 66,000 cases in 2028. All countries in the 7MM, except the US, will see a slight increase in diagnosed incident cases through the forecast period, according to GlobalData, a leading data and analytics company.
The company’s report: ‘Ovarian Cancer: Epidemiology Forecast to 2028’ found that in 2018, the US had the highest number of diagnosed incident and diagnosed prevalent cases of ovarian cancer.
However, the US is the only market that will see a decrease in cases at a negative AGR of 0.22% during the forecast period.
Nanthida Nanthavong, Epidemiologist at GlobalData, comments: “The decrease in incident cases in the US is due to an expected decrease in incidence rate during the forecast period for women ages 50 years and older, which can be attributed to decreased usage of menopausal hormones and increased usage of oral contraceptives, as well as changes in population. In the European markets and Japan, incidence will remain largely unchanged over the forecast period.”
Across all markets, diagnosing ovarian cancer continues to be difficult because symptoms can be non-specific and vague, resulting in a late diagnosis when the disease is in advanced stages.
Nanthavong concludes: “The ability to detect ovarian cancer at an early stage is a research priority, as patients diagnosed at an early stage are estimated to have a significantly higher five-year survival rate than patients with a late-stage diagnosis.”
*7MM: US, France, Germany, Italy, Spain, UK, and Japan.